Idexx Laboratories Reports Q4 EPS of $0.62

by Monica Gerson, Benzinga Staff Writer
January 28, 2011 7:11 AM | 15 seconds read |
Idexx Laboratories IDXX reports its Q4 diluted EPS at $0.62, versus the consensus of $0.55. IDXX reports its Q4 revenue at $238.8 million, versus the consensus of $279.22 million. IDXX shares fell 0.16% to $72.98 in after-hours trading. Read more from Benzinga's Company news.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Date
▲▼
ticker
▲▼
name
▲▼
Actual EPS
▲▼
EPS Surprise
▲▼
Actual Rev
▲▼
Rev Surprise
▲▼
Click to see more Earnings updates
Posted In: EarningsNewsEarningsHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!